Biopharma contributes to key global health discussions at WHA69
Find out here our take on the 69th World Health Assembly (WHA69) with some key relevant links included!
Read More
Pharmacovigilance of biotherapeutic medicines
A new study released in June 2016 identifying global case studies illustrating successes and challenges. A must read!
Read More
Our response to Zika virus
Check here about the R&D blueprint against Zika
Read More
Women’s Cancer Initiative in the Americas
Partnership to improve prevention of women’s cancers and quality of cancer registries in LAC reaches 1 year milestone
Read More
Latest News
2019-01-10 07:49:44
R&D biopharmaceutical industry embraces NEW Code of Practice to boost business integrity worldwide
The new Code of Practice in place from 1 January 2019, imposes a complete ban on gifts and promotional aids ...
Read More2018-12-10 13:14:17
Unjela Kaleem joins global pharma association as Director of Communications
Geneva, 10 December 2018 – IFPMA, the global research-based biopharmaceutical industry association, is pleased to ...
Read More2018-12-05 12:00:49
R&D biopharmaceutical industry revamp ethical code to apply as base line of industry behavior worldwide
New R&D biopharmaceutical industry Code of Practice comes into effect on 1 January 2019. Changes ...
Read More2018-12-04 17:17:22
David A. Ricks Elected New President of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
David A. Ricks, Chairman and Chief Executive Officer, Eli Lilly and Company, takes over as ...
Read More2018-11-16 06:30:08
Pharma industry launches call for coalition of countries to pilot new incentives for antibiotic R&D
16 November, Geneva – The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) draws attention ...
Read More2018-11-13 09:35:59
The largest private sector coalition to provide sustainable solutions to curb antimicrobial resistance (AMR) has made strides in 2018 and calls for a coordinated and multi-pronged response from all stakeholders
The AMR Industry Alliance has made major strides in 2018 taking action across four different ...
Read More2018-10-29 10:25:29
The R&D biopharmaceutical industry supports the Astana Declaration and renewed political commitment towards the importance of primary health care
26 October 2018, Astana – The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the ...
Read More
Latest Statement
2019-03-21 10:20:39
Statement on influenza vaccine supply in the 2019-20 Northern Hemisphere season
The WHO’s recommendations for the viruses (4 and 3 strains) to be included in influenza vaccines each season provide critical ...
Read More2019-02-06 10:17:10
EB 144 agenda item 5.5 Universal health coverage
26 October 2018, Astana – The International Federation of Pharmaceutical ...
Read More2019-01-30 16:13:53
EB 144 Fight the Fakes statement under agenda item 6.2 Member state mechanism on substandard and falsified medical products
26 October 2018, Astana – The International Federation of Pharmaceutical ...
Read More2019-01-30 15:05:26
EB 144 agenda item 6.1 Pandemic Influenza Preparedness Framework
26 October 2018, Astana – The International Federation of Pharmaceutical ...
Read More2019-01-30 09:25:33
EB 144 IFPMA statement under agenda item 5.8.2 Non-Communicable Diseases
26 October 2018, Astana – The International Federation of Pharmaceutical ...
Read More2019-01-29 18:39:25
EB 144 agenda item 5.7, “Technical” Report on Cancer Pricing
26 October 2018, Astana – The International Federation of Pharmaceutical ...
Read More2019-01-29 16:23:05
EB 144 IFPMA statement under agenda item 5.7, Access to Medicines and Vaccines Roadmap
26 October 2018, Astana – The International Federation of Pharmaceutical ...
Read More
mailto:s.kaenzig@ifpma.org +41 22 338 32 49
direct line
Twitter skaenzig
Sadia Kaenzig - Communications Manager
Sadia manages communications on issues including regulatory, intellectual property protection, trade and the economic footprint of the research-based pharmaceutical industry, research and development ecosystem and innovation, vaccines including influenza vaccines, and biotherapeutics.
mailto:m.depol@ifpma.org +41 22 338 32 20
direct line
Twitter @MorganePol
Morgane De Pol - Communications and Public Affairs
Morgane manages communications on issues including the research-based pharmaceutical industry’s commitment to achieving sustainable and inclusive development, advancing Universal Health Coverage, designing transformational partnerships to build healthier societies, boosting innovation for neglected tropical diseases, expanding access to high quality treatments for infectious and chronic diseases, fighting counterfeit medicines, and promoting resilient and efficient health systems.
Our Brouchure
2015 Edition
A shared commitment to global health
At IFPMA we advocate policies and practices that encourage the discovery of and access to life-saving and life-enhancing medicines and vaccines, for people everywhere.
Our Logo
Full colour EPS format
Our Logo
Full colour PNG format
FULL Name LOGO
Full colour EPS format
FULL Name LOGO
Full colour PNG format
Hot Topic
Pharmacovigilance: Do your bit, play your part!
Pharmacovigilance is one of the key steps to ensuring the safety of all our medicines, including biotherapeutics and vaccines. It encourages an ongoing cycle of communication between patients, health professionals, regulatory authorities, and our biopharma industry which is
Read MoreInterview
IFPMA 2015 interview series 'Biodiversity, human health, and pharma'
A must-watch: Dr Manisha A. Desai, assistant general patent counsel at Eli Lilly and Company, gives her take on the importance of the Convention of Biodiversity and the Nagoya Protocol for the pharma industry. What's key is to
Read MoreOur Blog
We are at a critical moment to invest in immunization
You’ve seen the alarming headlines from around the world: Asia, Europe, Africa, South America, and North America have seen the highest number of measles outbreaks in decades, and this disease once thought eliminated in many parts of the world is coming back with a vengeance. Why are we seeing such staggering rates of infections — and needless deaths — from a disease for which we have a safe and effective vaccine?...
Read More
Smart economics: the dividend of gender equality
This blog was first published on Pharma Boardroom on 8 March 2019. The jury is still out there regarding the impact of technological advancements on our overall life styles, but it’s hard to deny the positive impact technology has had on women’s social, political, economic and religious status in societies across the globe. Though we are still a long way from reaching equality, nevertheless campaigns...
Read More
Ethical business stimulates best value in health economy
This oped was first published on Pharma Focus Asia on 7 March 2019. Seventy years ago, average life expectancy globally was 47; today it is 72. Seventy years ago, 50 million people worldwide were infected with smallpox; today none. The disease is eradicated. Thanks to initiatives such as Gavi (the Vaccine Alliance), more than 80% of children now get early immunization. The world’s state of...
Read MoreLatest Tweets
@IFPMA @IFPMA @IFPMA @IFPMA @IFPMA 